Pharmacoidea’
Hungary-based biotechnology company (founded 2006) focused on drug discovery, preclinical R&D and nutraceutical product development. Activities include targeted drug delivery research, gene therapy vector work, biomarker discovery (metabolomics/glycomics), iPSC-derived disease models, and manufacturing of dietary supplement products. The company participates in multi‑partner national and international research projects and holds related patents.
Industries
Nr. of Employees
small (1-50)
Pharmacoidea’
Products
Nutraceutical formulations portfolio (consumer supplements)
A portfolio of science-based nutraceutical products spanning metabolic, digestive, bone & joint, nervous system, immune, cardiovascular, vision, liver, weight management and women's health categories. (Company indicates more than 40 formulations.)
Nutraceutical formulations portfolio (consumer supplements)
A portfolio of science-based nutraceutical products spanning metabolic, digestive, bone & joint, nervous system, immune, cardiovascular, vision, liver, weight management and women's health categories. (Company indicates more than 40 formulations.)
Services
Contract R&D services including bioassay development, preclinical validation, biomarker studies and model generation for neurodegenerative and infectious disease projects.
Development and manufacturing of science-based nutraceutical formulations and process optimization for supplement production.
Development of an AI-driven, Hungarian-language chatbot that offers personalized phytotherapy recommendations based on user data and scientific profiles of botanicals.
Contract R&D services including bioassay development, preclinical validation, biomarker studies and model generation for neurodegenerative and infectious disease projects.
Development and manufacturing of science-based nutraceutical formulations and process optimization for supplement production.
Development of an AI-driven, Hungarian-language chatbot that offers personalized phytotherapy recommendations based on user data and scientific profiles of botanicals.
Expertise Areas
- Drug discovery and preclinical R&D
- Targeted drug delivery
- Gene therapy vector research (AAV)
- Neurodegenerative disease therapeutics and diagnostics
Key Technologies
- Proteoglycan-mediated cellular delivery
- Adeno-associated virus (AAV) vectors
- Transgenic animal models
- Induced pluripotent stem cell (iPSC) astrocyte models
News & Updates
Company-hosted announcement referencing NEUROPA consortium funding to develop theranostic approaches for brain diseases.
Participation and leadership in multiple funded projects (examples include national ERA-NET, PIACI-KFI, COVINT, GINOP and others) supporting R&D in biomarkers, diagnostics, neurodegeneration and production capacity expansion.
Company markets a portfolio of nutraceutical formulations and actively seeks international distribution partners.
Leadership recognitions noted (examples include Enterprise Europe Network representative and national brand recognitions listed on the corporate site).
Company-hosted announcement referencing NEUROPA consortium funding to develop theranostic approaches for brain diseases.
Participation and leadership in multiple funded projects (examples include national ERA-NET, PIACI-KFI, COVINT, GINOP and others) supporting R&D in biomarkers, diagnostics, neurodegeneration and production capacity expansion.
Company markets a portfolio of nutraceutical formulations and actively seeks international distribution partners.
Leadership recognitions noted (examples include Enterprise Europe Network representative and national brand recognitions listed on the corporate site).